

cefTRIAxone 40 mg/mL in D5W IV Syringe (PEDS)

SUPPLIES

include quantity and medication name, strength/concentration, volume, diluent, diluent volume, and quantity and name of each supply needed

NS flush syringes are never to be used for reconstitution/diluent for medication.

Reconstituted solution is for single patient use only.

- One (1) cefTRIAxone 2 grams powder vial
- One (1) dextrose 5% in water (D5W) for injection, 50 mL bag
- Alcohol swabs
- Three (3) 18 gauge needles preferred (20-23 gauge needles acceptable)
- Two (2) 20 mL sterile IV syringe
- One (1) appropriate IV syringe size for patient specific dose
- Nursing IV admixture label(s) – Lawson #626

STEPS

explicitly state each step in chronological order, including hand washing, gown/garb, alcohol swab, etc.)

1. Wash hands. Prepare/clean the designated mixing area.
2. Flip the cap off of the ceftriaxone 2 grams powder vial, wipe the rubber stopper and the injection port of the D5W bag with alcohol swabs.
3. Attach 18 gauge needle to syringe. Withdraw 19.2 mL of D5W from the 50 mL D5W bag and transfer into cefTRIAxone vial to reconstitute. Shake vial thoroughly to mix. Discard syringe with needle into a sharp container.
4. Attach 18 gauge needle to syringe. Withdraw 20 mL of reconstituted ceftriaxone and transfer into the same D5W bag in #3, and discard syringe with needle into a sharp container.
5. Gently invert bag to mix. Do not shake. Visually inspect (e.g. free of inappropriate visible particulates or other foreign matter, discoloration, and defect), and the container integrity is intact. Discard if any defects.
6. Label cefTRIAxone 2 g/50 mL D5W bag (floor stock bag) with:
 - a. Drug name and strength (if not apparent by the container)
 - b. Diluent and volume (if not apparent by the container)
 - c. Hang-by date and time (**Administration must begin within 1 hour from the time of compounding**)
 - d. Initials of person compounding
7. Attach 18 gauge needle to appropriate size syringe and withdraw patient-specific dose/volume per order from floor stock bag. Discard the floor stock bag once dose is withdrawn.
8. Visually inspect syringe containing patient-specific dose for particulate matter/defects. Discard if any defects.
9. Label the final syringe with the following information:
 - i. Patient name and location
 - ii. Drug name, strength, and dose (if not apparent by the container)
 - iii. Diluent and volume (if not apparent by the container)
 - iv. Hang-by date and time (**Administration must begin within 1 hour from the time of dose withdrawn from floor stock bag**)
 - v. Initials of person compounding

References

- Ceftriaxone for injection [prescribing information]. Eatontown, NJ: WEST-WARD PHARMACEUTICALS. Revised 3/2023.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8351aa37-552d-471d-b293-c564dcb6ec29&type=display>.
- United States Pharmacopeia (USP). General Chapter, <797> Pharmaceutical Compounding—Sterile Preparations. (2023) USP-NF. Rockville, MD: United States Pharmacopeia.
<https://ochsnerhealth.sharepoint.com/sites/ClinicalResources/SiteAssets/Forms/AllItems.aspx?id=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness%2FUSP%2D797%2DOfficial%2D11%2E1%2E23%2Epdf&parent=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness>.